Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer
September 2nd 2022Sacituzumab govitecan displayed encouraging progression-free survival rates compared with single-agent chemotherapy in patients with locally recurrent inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer, according to findings from the phase 3 TROPiCS-02 study.
Read More
Erlotinib Displays Long-Term DFS Benefit, Meaningful OS Improvement vs Chemotherapy in EGFR+ NSCLC
September 1st 2022Erlotinib continued to elicit a disease-free survival and overall survival benefit vs vinorelbine/cisplatin chemotherapy in patients with EGFR-positive non–small cell lung cancer, according to updated OS data and an exploratory analysis from the phase 2 EVAN trial.
Read More
Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups
September 1st 2022Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.
Read More
Multidisciplinary Management Stands at the Forefront of Breast Cancer Treatment
August 29th 2022Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.
Read More
Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes
August 29th 2022Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.
Read More
Maintenance With Niraparib and Ipilimumab Demonstrates PFS Benefit in Pancreatic Cancer
August 23rd 2022Niraparib plus ipilimumab maintenance therapy elicited encouraging progression-free survival results in patients with advanced pancreatic cancer who achieved a stable response to platinum-based chemotherapy.
Read More
Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas
August 23rd 2022The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.
Read More
Perioperative Immunotherapy Demonstrates Promising pCR Rates in dMMR/MSI-H Gastric and GEJ Cancer
August 22nd 2022Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited positive pathologic complete response rates in patients with locally advanced resectable mismatch repair–deficient and/or microsatellite instability–high gastric or gastroesophageal junction adenocarcinoma.
Read More
Concurrent Galunisertib and Neoadjuvant Chemoradiotherapy Improves CR Rates in Rectal Cancer
August 19th 2022The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.
Read More
Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.
Read More
Immunotherapy Combinations Launch Into Earlier Lines and Signal Success in Metastatic Solid Tumors
August 17th 2022Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.
Read More
Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL
August 17th 2022Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.
Read More
Teclistamab Demonstrates Durable Response Rates in BCMA-Pretreated Multiple Myeloma
August 15th 2022Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.
Read More
Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC
August 12th 2022Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.
Read More
Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC
August 6th 2022Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.
Read More
Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.
Read More
Molecular Testing Continues to Predict Treatment Efficacy in Ovarian Cancer
July 22nd 2022Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.
Read More
Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL
July 20th 2022Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.
Read More
BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma
July 19th 2022Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.
Read More
Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer
July 15th 2022Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.
Read More
Seribantumab Demonstrates Positive Response Rates, Tolerability in NRG1 Fusion+ Solid Tumors
July 14th 2022Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE trial evaluating seribantumab and the importance of finding a targeted therapy for patients with solid tumors harboring NRG1 fusions.
Read More